Lyra therapeutics reports fourth quarter and full year 2024 financial results and provides corporate update

Watertown, mass., march 13, 2025 (globe newswire) -- lyra therapeutics, inc.  (nasdaq: lyra) (“lyra” or the “company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (crs), today reported its financial results for the fourth quarter and full year ended december 31, 2024 and provided a corporate update.
LYRA Ratings Summary
LYRA Quant Ranking